Skip to ContentSkip to Navigation
How to find us prof. dr. D. van Baarle

Research interests

My research focus is to understand the course of the immune response against virus infections and which characteristics play a role to protect against or control virus infections. To this end, we analyse quantitative as well as qualitative aspects of the cellular immune response at the level of antigen-presentation, immunodominance, and recognition by T cells. In addition, we perform in vitro studies to unravel the mechanisms underlying proper immune control.

We aim to elucidate differences related to 1) antigen-presentation by different HLA-molecules, 2) peptide properties presented by these HLA molecules and 3) features of T-cells restricted through different HLA-molecules with respect to function, phenotype and T cell receptor repertoire. Together, these studies will provide insight in features of T cells which are important for viral control (correlates of protection), which is crucial to improve vaccination strategies to induce proper immune responses for viral control.  

My current mission is to translate immunological correlates of protection from the individual patient to the population level enabling better vaccination strategies to protect against viral disease.

To this end I aim to bridge different public health related fields by using immunological knowledge and principles to address existing and future public health issues. This includes aging-related enhanced risk for infectious diseases, lifestyle and behavioral influences on immunological properties which may enhance the risk for infectious disease and reduce vaccine response.

To understand differences in immune responses at the population level, we will focus specifically on features that determine the effectiveness of the immune response, among which age, gender and genetic differences play a role as well as specific parts of the immune response like the available repertoire of immune cells. Previous encounters with micro-organisms can affect the immune repertoire and may influence the efficacy of the immune response. We aim to characterize the influence of previous encounters with vaccines and pathogens (infection history), including (coinfection with) specific herpesviruses, but also micro-organisms present in the intestine (gut microbiome) or airways on the immune response against new pathogens/infections or vaccines.

In relation to ageing and with a focus on healthy ageing and protecting the elderly population against infections, I initiated projects on the role of gut microbiome on respiratory infections and vaccine response in the young and old to identify microbial biomarkers of disease and vaccine response and set up model systems to unravel the causal pathways. In addition, in-depth analyses are performed on the role Cytomegalovirus on ageing and subsequent health consequences. Most recently, I  initiated an international consortium to study all aspects of Vaccines and infectious diseases in the aging population (VITAL), including epidemiology, immunology, modelling interventions and their impact, and communication programs, which was granted IMI funding within the H2020 EU program and started in January 2019. As part of this IMI grant we will perform a clinical vaccine study to identify biomarkers and immune signatures associated with (healthy) ageing and proper vaccine response. This is also part of the studies we are currently conducting in fril diseased patients in the context of SARS-CoV2 vaccination.

Read more


Associations of faecal microbiota with influenza-like illness in participants aged 60 years or older: an observational study

COVID-19 vaccination: the VOICE for patients with cancer

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant

The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant

Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors

Disruption of circadian rhythm by alternating light-dark cycles aggravates atherosclerosis development in APOE*3-Leiden.CETP mice

How age and infection history shape the antigen-specific CD8+ T-cell repertoire: Implications for vaccination strategies in older adults

Limited effect of duration of CMV infection on adaptive immunity and frailty: insights from a 27-year-long longitudinal study

Read more


Waarom er alle kans is dat u deze herfst verkouden en grieperig wordt

EMA: wacht nog even met derde prik voor álle burgers

Natuurlijke infectie beschermt beter! Waarom doen we er niet meer mee?

20210827 - 0818 Debbie Van Baarle - Afweersysteem En Vaccinaties

Onderzoek: eerdere coronabesmetting beschermt veel beter dan vaccin

Het Corona-effect Eerst besmet en dan geprikt levert beste bescherming op

Onderzoek: eerdere infectie beschermt veel beter dan vaccin

De sauna kan goed zijn voor je immuunsysteem, maar alleen als je 'm goed gebruikt én getraind bent

Dit is waarom er een prikstop is van het AstraZeneca-vaccin

‘Prikpauze houdt ons langer gevangen in pandemie’

Read more